ArticleHeart rhythm O22025
Proteomic biomarkers and biological pathways associated with atrial fibrillation in heart failure patients with reduced ejection fraction.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) and heart failure (HF) are intertwined conditions with high mortality and impact on quality of life. The biological mechanisms at play in patients with HF with vs without AF may differ. Objectives: This study aimed to describe differences in circulating proteins with putative pathophysiological effects between HF with reduced ejection fraction (HFrEF) patients with and without AF. Methods: We examined 377 patients with ambulant HFrEF and measured 4210 circulating proteins in baseline blood samples using an aptamer-based multiplex proteomic approach. Associations between AF (AF history or on baseline electrocardiogram) and the proteins were assessed using regression models adjusted for age, sex, kidney function, and duration of HF at baseline. Associations of AF-related proteins with biological processes were evaluated using enrichment analyses. Results: The median age [25th-75th percentile] was 64 years [55-72], 73% [274 of 377] were male, 28% [104 of 375] had New York Heart Association class III/IV, and 37% [139 of 377] had AF (either AF history [36%, 137 of 377] or AF on baseline electrocardiogram [8%, 30 of 374]). We found 71 proteins significantly associated with AF (false discovery rate < .05), including well-studied (eg, troponin T, insulin-like growth factor-binding protein 7, microfibril-associated glycoprotein 4, bone morphogenetic protein 10, angiopoietin 2) and lesser-studied proteins (eg, olfactomedin-like protein 3, keratocan, basigin) in the AF domain. Our pathway analysis revealed modules of proteins related to various underlying mechanisms, such as nervous system development, elastic fiber assembly, protein glycosylation, and ether lipid metabolism. Conclusions: Patients with HFrEF with AF have distinct circulating proteomic profiles, and these differences are related to various biological mechanisms. This study provides an overview of the systemic biological pathways associated with AF in patients with HFrEF, confirms (pre-)clinical findings regarding AF-related proteins, and could inform future research in novel treatment targets and HFrEF-AF management after careful validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.